Rohit Mittal1, Ching-Wen Chen1, John D Lyons1, Lindsay M Margoles2, Zhe Liang1, Craig M Coopersmith1, Mandy L Ford3. 1. Department of Surgery and Emory Critical Care Center, Emory University School of Medicine, Atlanta, Georgia. 2. Department of Infectious Diseases and Emory Critical Care Center, Emory University School of Medicine, Atlanta, Georgia. 3. Department of Surgery and Emory Transplant Center, Emory University School of Medicine, Atlanta, Georgia. Electronic address: mandy.ford@emory.edu.
Abstract
BACKGROUND: Cancer is known to modulate tumor-specific immune responses by establishing a microenvironment that leads to the upregulation of T-cell inhibitory receptors, resulting in the progressive loss of function and eventual death of tumor-specific T-cells. However, the ability of cancer to impact the functionality of the immune system on a systemic level is much less well characterized. Because cancer is known to predispose patients to infectious complications including sepsis, we hypothesized that the presence of cancer alters pathogen-directed immune responses on a systemic level. MATERIALS AND METHODS: We assessed systemic T-cell coinhibitory receptor expression, cytokine production, and apoptosis in mice with established subcutaneous lung cancer tumors and in unmanipulated mice without cancer. RESULTS: Results indicated that the frequencies of programmed death-1-positive, B and T lymphocyte attenuator-positive, and 2B4(+) cells in both the CD4(+) and CD8(+) T-cell compartments were increased in mice with localized cancer relative to non-cancer controls, and the frequencies of both CD4(+) and CD8(+) T-cells expressing multiple different inhibitory receptors were increased in cancer animals relative to non-cancer controls. Additionally, 2B4(+)CD8(+) T-cells in cancer mice exhibited reduced interleukin-2 and interferon-γ, whereas B and T lymphocyte attenuator-positive CD8(+) T-cells in cancer mice exhibited reduced interleukin-2 and tumor necrosis factor. Conversely, CD4(+) T-cells in cancer animals demonstrated an increase in the frequency of annexin V(+) apoptotic cells. CONCLUSIONS: Taken together, these data suggest that the presence of cancer induces systemic T-cell exhaustion and generalized immune suppression.
BACKGROUND:Cancer is known to modulate tumor-specific immune responses by establishing a microenvironment that leads to the upregulation of T-cell inhibitory receptors, resulting in the progressive loss of function and eventual death of tumor-specific T-cells. However, the ability of cancer to impact the functionality of the immune system on a systemic level is much less well characterized. Because cancer is known to predispose patients to infectious complications including sepsis, we hypothesized that the presence of cancer alters pathogen-directed immune responses on a systemic level. MATERIALS AND METHODS: We assessed systemic T-cell coinhibitory receptor expression, cytokine production, and apoptosis in mice with established subcutaneous lung cancer tumors and in unmanipulated mice without cancer. RESULTS: Results indicated that the frequencies of programmed death-1-positive, B and T lymphocyte attenuator-positive, and 2B4(+) cells in both the CD4(+) and CD8(+) T-cell compartments were increased in mice with localized cancer relative to non-cancer controls, and the frequencies of both CD4(+) and CD8(+) T-cells expressing multiple different inhibitory receptors were increased in cancer animals relative to non-cancer controls. Additionally, 2B4(+)CD8(+) T-cells in cancermice exhibited reduced interleukin-2 and interferon-γ, whereas B and T lymphocyte attenuator-positive CD8(+) T-cells in cancermice exhibited reduced interleukin-2 and tumor necrosis factor. Conversely, CD4(+) T-cells in cancer animals demonstrated an increase in the frequency of annexin V(+) apoptotic cells. CONCLUSIONS: Taken together, these data suggest that the presence of cancer induces systemic T-cell exhaustion and generalized immune suppression.
Authors: Claudia C Preston; Ellen L Goode; Lynn C Hartmann; Kimberly R Kalli; Keith L Knutson Journal: Immunotherapy Date: 2011-04 Impact factor: 4.196
Authors: Rohit Mittal; Maylene Wagener; Elise R Breed; Zhe Liang; Benyam P Yoseph; Eileen M Burd; Alton B Farris; Craig M Coopersmith; Mandy L Ford Journal: PLoS One Date: 2014-05-05 Impact factor: 3.240
Authors: Shawn D Blackburn; Haina Shin; W Nicholas Haining; Tao Zou; Creg J Workman; Antonio Polley; Michael R Betts; Gordon J Freeman; Dario A A Vignali; E John Wherry Journal: Nat Immunol Date: 2008-11-30 Impact factor: 25.606
Authors: John D Lyons; Ching-Wen Chen; Zhe Liang; Wenxiao Zhang; Deena B Chihade; Eileen M Burd; Alton B Farris; Mandy L Ford; Craig M Coopersmith Journal: Shock Date: 2019-06 Impact factor: 3.454
Authors: Clara S Mundry; Kirsten C Eberle; Pankaj K Singh; Michael A Hollingsworth; Kamiya Mehla Journal: Biochim Biophys Acta Rev Cancer Date: 2020-06-21 Impact factor: 10.680
Authors: Alexandra M Miggelbrink; Joshua D Jackson; Selena J Lorrey; Ethan S Srinivasan; Jessica Waibl-Polania; Daniel S Wilkinson; Peter E Fecci Journal: Clin Cancer Res Date: 2021-06-14 Impact factor: 12.531
Authors: Minhong Shen; Shanshan Xie; Michelle Rowicki; Sven Michel; Yong Wei; Xiang Hang; Liling Wan; Xin Lu; Min Yuan; John F Jin; Frank Jaschinski; Tianhua Zhou; Richard Klar; Yibin Kang Journal: Cancer Res Date: 2020-11-25 Impact factor: 13.312
Authors: John D Lyons; Rohit Mittal; Katherine T Fay; Ching-Wen Chen; Zhe Liang; Lindsay M Margoles; Eileen M Burd; Alton B Farris; Mandy L Ford; Craig M Coopersmith Journal: PLoS One Date: 2016-03-28 Impact factor: 3.240
Authors: Jianfeng Xie; Jennifer M Robertson; Ching-Wen Chen; Wenxiao Zhang; Craig M Coopersmith; Mandy L Ford Journal: PLoS One Date: 2018-01-16 Impact factor: 3.240